Investing for the Next 12 Months? Buy These
If investors expect interest rates to hold until next year, they should consider dividend-yielding stocks like Altria (NYSE: MO), Bristol Myers, and Pfizer (NYSE: PFE), which offer reasonable value...
Kansas sues Pfizer, saying it misled the public over COVID-19 vaccine
The state of Kansas has filed a lawsuit against Pfizer alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine including by working to censor critical info...
Kansas sues Pfizer alleging it ‘misled' the public about safety of COVID vaccine
Kansas Attorney General Kris Kobach says Pfizer ‘violated' the Consumer Protection Act on ‘The Bottom Line.' #foxbusiness #thebottomline
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products.
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Pfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. In contrast, Merck stock is up 36% over this period.
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavil...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon
A difficult period for Pfizer might be coming to an end, as serious setbacks and tough Y/Y comps are in the rearview mirror. The first quarter performance of the commercial business exceeded Street...
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.
Pfizer: Too Cheap To Miss Out
Pfizer's stock is currently trading below pre-pandemic levels, despite the record-breaking year it had in 2023 for FDA approvals and the significant acquisition of Seagen. Weak sentiment is likely ...
3 Discounted Stocks Poised for a Major Upswing
Due to their robust financial and strategic approaches, these three equities are all seeing notable progress in their respective industries. Recent financial results for the first one show robust r...
Is Pfizer the Best Dividend Stock for You?
Pfizer's COVID-19 vaccine revenue is drying up. But the company's push into oncology should reignite growth.
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Pfizer expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 after most patients treated for a form of lung cancer had no disease progression after five years.
Pfizer's drug for advanced lung cancer shows promising long-term trial results
Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which could help establish it as the new standard treatment for the cond...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Pfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the strength of data presented on Friday showing most patients treated for a rare form of advanced lung ...
Related Companies